This Biotech Is One of the S&P 500’s Worst Performers. It Looks

Moderna stock, down over 50% this year to $43, is one of the worst performers in the S&P 500. It also looks too cheap. Shares have been hammered by disappointing Covid vaccine sales, the …

50%
OFF

This Biotech Is One Of The S&P 500’s Worst Performers. It Looks

2 weeks from now

Moderna stock, down over 50% this year to $43, is one of the worst performers in the S&P 500. It also looks too cheap. Shares have been hammered by disappointing Covid vaccine sales, the …

msn.com

$9
OFF

This Biotech Is One Of The S&P 500’s Worst Performers. It Looks …

2 weeks from now

Shares of Moderna have been hammered by disappointing Covid vaccine sales, the company’s heavy losses—an estimated $9 a share for 2024—and management’s move to push out the …

barrons.com

30%
OFF

These Are The 5 Worst-Performing Stocks In The S&P 500

2 weeks from now

2024 has been a generally outstanding year for the stock market, with the S&P 500 (SNPINDEX: ^GSPC) up by nearly 30% year to date as of Dec. 11. However, not all stocks have performed …

barchart.com

65%
OFF

Is Now The Time To Buy 3 Of The S&P 500's Worst-Performing …

2 weeks from now

Dec 5, 2024 · Among the S&P 500's worst performers thus far in 2024 are Walgreens Boots Alliance (WBA-4.65%), Moderna (MRNA-9.17%), and Intel (INTC-0.65%). Below, I'll look at …

fool.com

76%
OFF

Worst Performing Biotechnology Stocks Last 12 Months

2 weeks from now

The worst performing biotechnology stock in the world for the past 12 months is Nykode Therapeutics ASA (VACBF) with a total return of -84.76%, followed by RemeGen (REGMF) …

financecharts.com

28%
OFF

Why Is BioMarin Pharmaceutical Inc. (BMRN) Among The Worst …

2 weeks from now

The stock has fallen by nearly 28% since the start of 2024, which makes it one of the worst performing biotech stocks on our list. In the latest quarter, BioMarin Pharmaceutical Inc. …

msn.com

FAQs about This Biotech Is One of the S&P 500’s Worst Performers. It Looks Coupon?

Is the S&P 500 doing worse?

Even with the broad market index down so far this year, this quartet is doing even worse. After looking like it was about to plunge into correction territory, the S&P 500 has pared its losses for the new year by almost half after notching several days of gains. ...

Is the S&P 500 a good investment?

The S&P 500 has hit record levels this year and many stocks have generated fantastic returns for investors. But there's been no shortage of struggling investments, either. Many companies that have been finding it difficult to grow and that may not have any near-term catalysts on the horizon have seen their shares fall sharply this year. ...

Is it time to buy the S&P 500's 4 worst-performing stocks?

Corrections and bear markets are good times to buy stocks, but caution is still needed. Sometimes a badly beaten down stock is cheap for a reason. ...

Will there be a spike in Biotech IPOs?

Although it's a good step, Mizuho Securities analyst Jared Holz thinks it's unlikely that there will be a spike in fundraising, M&A transactions, or IPOs. A lot of biotech businesses have canceled programs and made large layoffs to save money in an attempt to survive in volatile markets. ...

Why are biotech stocks so volatile?

Biotechnology stocks are among the most volatile in the market due to their high risk. The outcomes of FDA clinical trials and the effectiveness of their therapies in the real world might cause significant fluctuations in their pricing. The introduction of COVID-19 vaccinations in 2020 caused the biotech industry to soar to prominence. ...

Is the biopharma sector still a tailwind?

Here is what she said about the sector: “We still see tailwinds for the industry going forward. Smaller-cap names are still targets for acquisitions by bigger biopharma firms, and a wave of acquisitions has continued since late last year, particularly focused on oncology and immunology. ...